[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646147":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":18,"collaborators":10,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":10,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":30,"maxAge":31,"enrollmentInfo":32,"targetDuration":10,"studyType":35,"phases":10,"briefSummary":36,"conditions":37,"keywords":40,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"Helwan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients receiving cyclosporine to prevent graft-versus-host disease after HSCT.",null,"Participants undergoing allogeneic hematopoietic stem cell transplantation who received cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Cyclosporine was administered according to institutional practice, and blood concentration measurements obtained during routine therapeutic drug monitoring were used to develop and evaluate a model-informed precision dosing algorithm.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Yasmin Mohammed, demonstrater assitant","CONTACT","+201093201956","Yasmin.Mohammed@pharm.capu.edu.eg",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Yasmin medhat munir Mohamed","demonstrater assistant","100646147","model-informed-precision-dosing-on-cyclosporine-therapy-in-hematopoietic-stem-cell-transplant-recipients-100646147",false,"NCT07695571","Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients","Hybrid Population Pharmacokinetic,Machine Learning and Deep Learning Modelling to Predict Dosing for the Individualization of Cyclosporine Therapy in Transplant Recipients","Inclusion Criteria:\n\n* • CsA therapy indicated alone or in combination for GVHD prophylaxis.\n\n  * Aged 2-65 years.\n  * Clinically stable after first HSCT.\n\nExclusion Criteria:\n\n* • Inaccurate sampling or dose administration times.\n\n  * Patients with missing key covariates.\n  * Patients lacking sufficient pharmacokinetic or TDM data","ALL","2 Years","65 Years",{"count":33,"type":34},300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a new tool that helps doctors choose the right cyclosporine dose for patients undergoing bone marrow transplantation. The tool is designed to predict the best dose using sparse sampling, making it practical for everyday clinical care. It combines information about population pharmacokinetics of cyclosporine with advanced artificial intelligence techniques, including machine learning and deep learning. This tool aims to improve treatment, personalize dosing for each patient, and reduce the risk of graft-versus-host disease.",[38,39],"Bone Marrow Transplantation","AML",[41,42],"Clinical Pharmacokinetics","Machine learning","NOT_YET_RECRUITING","2026-07-08",{"date":46,"type":47},"2026-07-10","ACTUAL",{"date":49,"type":34},"2026-08-01",{"date":51,"type":34},"2027-06-01",{"name":20,"class":6}]